Close

Antagonistic Antibody in Metabolic Diseases

Recombinant monoclonal antibodies with an agonistic or antagonistic effect can be promising therapeutic molecules in terms of human diseases treatments. As a well-recognized leader in the antibody engineering field, Creative Biolabs offers a series of high-quality services of recombinant antibodies with agonistic or antagonistic activity for both academic and clinical use.

Introduction to Antagonistic Antibody

Agonistic and antagonistic antibody as a novel antibody category has drawn much attention in immunotherapy. Obviously, agonistic antibodies are these immunoglobulins bind to the receptor in a manner that mimics the binding of the natural ligand leading to the activation of the downstream signaling or agonism. On the contrary, antibodies bind to the receptor resulting in the block of the signaling pathway or antagonism are named as the antagonistic antibody. Both agonistic antibody and antagonistic antibody are extensively investigated and applied in clinical development for diseases treatment.

Different from agonist antibodies that mainly target immune co‑stimulatory receptors (responsible for immune response to eliminate antigens), antagonist antibodies are designed to against those co‑inhibitory receptors (responsible for inhibiting signaling to avoid excessive immune activation) to achieve therapeutic effects. Currently, the most widely researched and applied antagonist antibodies are recombinant monoclonal antibodies against immune checkpoints, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and lymphocyte activation gene 3 (LAG-3).

The immune checkpoint modulators (including antagonistic and agonistic antibodies). Fig.1 The immune checkpoint modulators (including antagonistic and agonistic antibodies). (Berman, 2015)

Antagonistic Antibody Application in Metabolic Diseases

Metabolism is the general term for all chemical reactions in organisms as well as the basis for energy supply and tissue balance. Metabolic diseases will be induced when the normal metabolism is disrupted, the reason of which may be mainly caused by genetic factors and acquired organ dysfunction. Metabolic diseases are a large category including many diseases, such as diabetes, ion metabolism disorders, metabolic syndrome X, etc. The treatment of metabolic disorders depends on the specific type of metabolic disease, mainly including diet management and drug control.

It is exciting that a panel of antagonistic antibodies shows great potential for several metabolic diseases treatment. For instance, the antagonistic effect mediated by a chicken monoclonal antibody against glucose-dependent insulinotropic polypeptide (GIP) receptor exhibited great value on the treatment of diabetes and obesity, by which the antibody increased the insulin sensitivity, enhanced metabolism of cholesterol and triglyceride, and inhibited diet-induced obesity (Könitzer, 2017). Toll-like receptors (TLRs) antagonist monoclonal antibodies are promising molecules for therapeutic intervention of inflammations, metabolic syndrome, and autoimmune diseases.

Agonistic and Antagonistic Antibody Services in Creative Biolabs

Relying on our unparalleled expertise and well-established comprehensive antibody platforms, Creative Biolabs is committed to satisfying the needs of our customers for a wide range of antibody types. At present, our Ph.D. scientists are fully confident in providing global customers with quantities of agonistic and antagonistic antibody services, which mainly include but not limited to:

Please feel free to contact us for more detailed communications and information. Our scientists are confident in offering satisfying and the best answers and services.

References

  1. Berman, D.; et al. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacology & Therapeutics. 2015, 148: 132-153.
  2. Könitzer, J.D.; et al. Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor. MAbs. 2017, 9(3): 536-549.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us